News-Medical.Net October 16, 2024
Dr. Chinta Sidharthan

As AI technology evolves rapidly, the FDA is tackling the challenge of balancing innovation with patient safety, shaping regulations that ensure AI tools remain effective throughout their entire lifecycle.

A Special Communication published in the Journal of the American Medical Association (JAMA) examined the regulation of artificial intelligence (AI) in healthcare by the United States (U.S.) Food and Drug Administration (FDA). It also explored AI’s potential in clinical research, development of medical products, and patient care while highlighting the key areas to address as regulations are adapted for some of AI’s distinctive challenges in biomedicine and healthcare.

Background

Advances in AI have immense potential for transforming biomedicine and healthcare. Expectations from AI often exceed those from previous medical technologies such...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: AI (Artificial Intelligence), FDA, Govt Agencies, Healthcare System, Patient / Consumer, Provider, Regulations, Safety, Technology
Related Articles:
Opinion: STAT+: How the FDA and CMS worked together on a new approach to paying for digital mental health treatments
FDA Nod Paves Way for AstraZeneca Drug to Become New Standard of Care in Rare Blood Cancer
FDA's health kick: New food labels, banned food dyes, and more
FDA Releases Draft Guidance on Evaluating the Risk and Credibility of AI Used in Establishing Drug and Device Safety, Effectiveness, and Quality
JPM25: The FDA’s future, AbbVie’s second thoughts and Lilly’s lesson

Share This Article